|Table of Contents|

Research progress of ASCT2 in cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 01
Page:
115-121
Research Field:
Publishing date:

Info

Title:
Research progress of ASCT2 in cancer
Author(s):
WANG Chunxia1; ZHANG Di1; ZHAO Lixia1; YANG Xiongfei2; 3; ZHANG Weisheng2; 3; WANG Tao2; 3
1.The First Clinical Medical College of Gansu University of Chinese Medicine,Gansu Lanzhou 730000,China;2.Department of Anorectal,Gansu Provincial People's Hospital,Gansu Lanzhou 730000,China;3.Gansu Provincial Clinical Medical Research Center for Anorectal Diseases，Gansu Lanzhou 730000,China.
Keywords:
ASCT2; glutamine; cancer
PACS:
R730
DOI:
10.3969/j.issn.1672-4992.2025.01.019
Abstract:
Glutamine metabolic reprogramming is a very important biological feature in the development of cancer,and is one of the important energy sources for the rapid growth of tumor.Some cancer cells cannot survive in the absence of exogenous glutamine,showing glutamine-addictive characteristics.They rely on the hyperactive glutamine transport system to transport large amounts of glutamine into tumor cells to maintain their energy requirements.alanine-serine-cysteine amino acid transporter-2 (ASCT2) is a glutamine transporter with high affinity,which is involved in the malignant process of many tumors by regulating amino acid metabolism reprogramming.In this paper,the structure and function of ASCT2 and its mechanism of regulating cancer were reviewed.

References:

［1］ XIA L,OYANG L,LIN J,et al.The cancer metabolic reprogramming and immune response ［J］.Mol Cancer,2021,20(1):28-49.
［2］ DANZI F,PACCHIANA R,MAFFICINI A,et al.To metabolomics and beyond:a technological portfolio to investigate cancer metabolism ［J］.Signal Transduct Target Ther,2023,8(1):137-158.
［3］ LI Z,SUN C,QIN Z.Metabolic reprogramming of cancer-associated fibroblasts and its effect on cancer cell reprogramming ［J］.Theranostics,2021,11(17):8322-8336.
［4］ XIAOYAN W,XIAOXIA Y,PENGFEI S,et al.Metabolic reprogramming of glutamine involved in tumorigenesis,multidrug resistance and tumor immunity ［J］.Eur J Pharmacol,2022,940:175323.
［5］ LEE KT,LIAO HS,HSIEH MH.Glutamine metabolism,sensing and signaling in plants ［J］.Plant Cell Physiol,2023,64(12):1466-1481.
［6］ TEIXEIRA E,SILVA C,MARTEL F.The role of the glutamine transporter ASCT2 in antineoplastic therapy ［J］.Cancer Chemother Pharmacol,2021,87(4):447-464.
［7］ FUCHS BC,BODE BP.Amino acid transporters ASCT2 and LAT1 in cancer:partners in crime［J］.Semin Cancer Biol,2005,15(4):254-266.
［8］ FUCHS BC,PEREZ JC,SUETTERLIN JE,et al.Inducible antisense RNA targeting amino acid transporter ATB0/ASCT2 elicits apoptosis in human hepatoma cells ［J］.Am J Physiol Gastrointest Liver Physiol,2004,286(3):467-478.
［9］ YOO HC,PARK SJ,NAM M,et al.A variant of SLC1A5 is a mitochondrial glutamine transporter for metabolic reprogramming in cancer cells ［J］.Cell Metab,2020,31(2):267-283.
［10］ GALAN-COBO A,SITTHIDEATPHAIBOON P,QU X,et al.LKB1 and KEAP1/NRF2 pathways cooperatively promote metabolic reprogramming with enhanced glutamine dependence in KRAS-mutant lung adenocarcinoma ［J］.Cancer Res,2019,79(13):3251-3267.
［11］ ZHANG Z,LIU R,SHUAI Y,et al.ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma ［J］.Br J Cancer,2020,122(1):82-93.
［12］ SCALISE M,CONSOLE L,COSCO J,et al.ASCT1 and ASCT2:Brother and sister［J］.SLAS Discov,2021,26(9):1148-1163.
［13］ SCALISE M,POCHINI L,PINGITORE P,et al.Cysteine is not a substrate but a specific modulator of human ASCT2 (SLC1A5) transporter ［J］.FEBS Lett,2015,589(23):3617-3623.
［14］ FREIDMAN N,CHEN I,WU Q,et al.Amino acid transporters and exchangers from the SLC1A family:structure,mechanism and roles in physiology and cancer ［J］.Neurochem Res,2020,45(6):1268-1286.
［15］ KORTZAK D,ALLEVA C,WEYAND I,et al.Allosteric gate modulation confers K(+) coupling in glutamate transporters ［J］.Embo J,2019,38(19):e101468.
［16］ SCALISE M,POCHINI L,CONSOLE L,et al.Cys site-directed mutagenesis of the human SLC1A5 (ASCT2) transporter:Structure/function relationships and crucial role of Cys467 for redox sensing and glutamine transport ［J］.Int J Mol Sci,2018,19(3):648-664.
［17］ BJEDOV I,RALLIS C.The target of rapamycin signalling pathway in ageing and lifespan regulation ［J］.Genes (Basel),2020,11(9):1043-1064.
［18］ WANG Y,ZHANG H.Regulation of autophagy by mTOR signaling pathway ［J］.Adv Exp Med Biol,2019,1206:67-83.
［19］ DU D,LIU C,QIN M,et al.Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma ［J］.Acta Pharm Sin B,2022,12(2):558-580.
［20］ DIAS F,ALMEIDA C,TEIXEIRA AL,et al.LAT1 and ASCT2 related microRNAs as potential new therapeutic agents against colorectal cancer progression ［J］.Biomedicines,2021,9(2):195-213.
［21］ VAN GELDERMALSEN M,WANG Q,NAGARAJAH R,et al.ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer ［J］.Oncogene,2016,35(24):3201-3208.
［22］ WANG W,PAN H,REN F,et al.Targeting ASCT2-mediated glutamine metabolism inhibits proliferation and promotes apoptosis of pancreatic cancer cells ［J］.Biosci Rep,2022,42(3):BSR20212171.
［23］ NI J,DAI W,LIU C,et al.A pan-cancer analysis of SLC1A5 in human cancers ［J］.Heliyon,2023,9(6):e17598.
［24］ CHEN M,WANG G,XU Z,et al.Loss of RACK1 promotes glutamine addiction via activating AKT/mTOR/ASCT2 axis to facilitate tumor growth in gastric cancer ［J］.Cell Oncol (Dordr),2024,47(1):113-128.
［25］ YU W,HUANG J,DONG Q,et al.Ag120-mediated inhibition of ASCT2-dependent glutamine transport has an anti-tumor effect on colorectal cancer cells ［J］.Front Pharmacol,2022,13:871392.
［26］ WORTEL IMN,VAN DER MEER LT,KILBERG MS,et al.Surviving stress:modulation of ATF4-mediated stress responses in normal and malignant cells ［J］.Trends Endocrinol Metab,2017,28(11):794-806.
［27］ CHEN X,CUBILLOS-RUIZ JR.Endoplasmic reticulum stress signals in the tumour and its microenvironment ［J］.Nat Rev Cancer,2021,21(2):71-88.
［28］ ZIELKE S,KARDO S,ZEIN L,et al.ATF4 links ER stress with reticulophagy in glioblastoma cells ［J］.Autophagy,2021,17(9):2432-2448.
［29］ TAMEIRE F,VERGINADIS II,LELI NM,et al.ATF4 couples MYC-dependent translational activity to bioenergetic demands during tumour progression ［J］.Nat Cell Biol,2019,21(7):889-899.
［30］ SZEWCZYK MM,LUCIANI GM,VU V,et al.PRMT5 regulates ATF4 transcript splicing and oxidative stress response［J］.Redox Biol,2022,51:102282.
［31］ REN P,YUE M,XIAO D,et al.ATF4 and N-Myc coordinate glutamine metabolism in MYCN-amplified neuroblastoma cells through ASCT2 activation ［J］.J Pathol,2015,235(1):90-100.
［32］ 任平.谷氨酰胺转运体ASCT2在MYCN扩增的神经母细胞瘤中的生物学功能及分子调控机制研究 ［D］.武汉：华中科技大学,2014:1-119. Ren P.Biological function and molecular regulation of glutamine transporter ASCT2 in MyCN-amplified neuroblastoma ［D］.Wuhan:Huazhong University of Science and Technology,2014:1-119.
［33］ HUANG S.mTOR signaling in metabolism and cancer ［J］.Cells,2020,9(10)2278-2282.
［34］ NICKLIN P,BERGMAN P,ZHANG B,et al.Bidirectional transport of amino acids regulates mTOR and autophagy ［J］.Cell,2009,136(3):521-534.
［35］ KIM G,JANG SK,KIM YJ,et al.Inhibition of glutamine uptake resensitizes paclitaxel resistance in SKOV3-TR ovarian cancer cell via mTORC1/S6K signaling pathway ［J］.Int J Mol Sci,2022,23(15):8761-8776.
［36］ HARA Y,MINAMI Y,YOSHIMOTO S,et al.Anti-tumor effects of an antagonistic mAb against the ASCT2 amino acid transporter on KRAS-mutated human colorectal cancer cells ［J］.Cancer Med,2020,9(1):302-312.
［37］ SCHULTE ML,FU A,ZHAO P,et al.Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models ［J］.Nat Med,2018,24(2):194-202.
［38］ AI C,SUN X,XIAO S,et al.CAFs targeted ultrasound-responsive nanodroplets loaded V9302 and GLULsiRNA to inhibit melanoma growth via glutamine metabolic reprogramming and tumor microenvironment remodeling ［J］.J Nanobiotechnology,2023,21(1):214-234.
［39］ EDWARDS DN,NGWA VM,RAYBUCK AL,et al.Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer ［J］.J Clin Invest,2021,131(4):e140100.
［40］ BAGUET T,BOUTON J,JANSSENS J,et al.Radiosynthesis,in vitro and preliminary biological evaluation of ［(18) F］2-amino-4-((2-((3-fluorobenzyl)oxy)benzyl)(2-((3-(fluoromethyl)benzyl)oxy)benzyl)amino)butanoic acid,a novel alanine serine cysteine transporter 2 inhibitor-based positron emission tomography tracer ［J］.J Labelled Comp Radiopharm,2020,63(10):442-455.
［41］ POLLARD AC,PAOLILLO V,RADARAM B,et al.PET/MR imaging of a lung metastasis model of clear cell renal cell carcinoma with (2S,4R)-4-［(18)F］fluoroglutamine ［J］.Mol Imaging Biol,2022,24(6):959-972.
［42］ BHUTIA YD,GANAPATHY V.Glutamine transporters in mammalian cells and their functions in physiology and cancer ［J］.Biochim Biophys Acta,2016,1863(10):2531-2539.
［43］ SCALISE M,POCHINI L,CONSOLE L,et al.The human SLC1A5 (ASCT2) amino acid transporter:From function to structure and role in cell biology ［J］.Front Cell Dev Biol,2018,6:96-113.
［44］ LIU Y,ZHAO T,LI Z,et al.The role of ASCT2 in cancer:A review ［J］.Eur J Pharmacol,2018,837:81-87.

Memo

Memo:
National Natural Science Foundation of China(No.82160522);国家自然科学基金（编号：82160522）；甘肃省自然科学基金项目(编号：22JR5RA653,22JR5RA676)
Last Update: 1900-01-01